Clara Yieh Lin Chong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Clara Yieh Lin Chong has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Angie Tan
Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore, Singapore
14 shared publications - Chin Jin Seo
Department of Sarcoma, Peritoneal and Rare Tumors (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore, Singapore, Singapore
14 shared publications - Chin-Ann Johnny Ong
Laboratory of Applied Human Genetics, Division of Medical Sciences, National Cancer Centre Singapore, Singapore, Singapore
14 shared publications - Claramae S. Chia
Department of Sarcoma, Peritoneal and Rare Tumors (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore, Singapore, Singapore
14 shared publications - Craig Ryan Cecil Joseph
Agency for Science, Technology and Research (A*STAR) 14 Integrated Central Operations and Research Enablers Singapore, Singapore
14 shared publications - Daryl Kai Ann Chia
National University Hospital 19 Department of Surgery Singapore, Singapore
14 shared publications
Latest Publications
- Open Access
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis
Supplementary Table 4. Comparisons of histological features between SC1 and SC2.
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis
Supplementary Table 4. Comparisons of histological features between SC1 and SC2.
- Open Access
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Methods 1 from Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis
Supplementary Methods 1. Supplementary Methods, DNA extraction and whole exome sequencing, Mutation calling and mutational signatures, Whole transcriptome sequencing, Spatial profiling, Methods of A5 Discovery and Validation, Other statistical methods and reproducibility.
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods 1 from Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis
Supplementary Methods 1. Supplementary Methods, DNA extraction and whole exome sequencing, Mutation calling and mutational signatures, Whole transcriptome sequencing, Spatial profiling, Methods of A5 Discovery and Validation, Other statistical methods and reproducibility.
- Open Access
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis
Supplementary Figure 1. Quality control parameters for WES data utilized in the study.
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis
Supplementary Figure 1. Quality control parameters for WES data utilized in the study.
- Open Access
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis
Supplementary Table 2. Gene signatures, target genes, and whole transcriptome derivatives.
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis
Supplementary Table 2. Gene signatures, target genes, and whole transcriptome derivatives.
- Open Access
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis
Supplementary Table 3. Spatial QC metrics and cell type markers.
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis
Supplementary Table 3. Spatial QC metrics and cell type markers.
- Open Access
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis
Supplementary Table 5. T-test comparisons between DSP ROIs and top 20 (10 up and 10 down) discriminatory genes.
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis
Supplementary Table 5. T-test comparisons between DSP ROIs and top 20 (10 up and 10 down) discriminatory genes.
- Open Access
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis
Supplementary Figure 6. Safety profile of intravenous injection of A5.
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis
Supplementary Figure 6. Safety profile of intravenous injection of A5.
- Open Access
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis
Supplementary Table 1. Cohort and sample overview.
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis
Supplementary Table 1. Cohort and sample overview.
- Open Access
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis
Supplementary Table 6. A5 in mouse models.
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis
Supplementary Table 6. A5 in mouse models.
- Open Access
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis
Supplementary Figure 2. Niche remodelling and prognostic significance of SERPINE1.
- 13 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Spatial Heterogeneity, Stromal Phenotypes, and Therapeutic Vulnerabilities in Colorectal Cancer Peritoneal Metastasis
Supplementary Figure 2. Niche remodelling and prognostic significance of SERPINE1.